A case of rivaroxaban associated intracranial hemorrhage

Western Journal of Emergency Medicine

Volumn 15, Issue 4, 2014, Pages 375-377

  Lo, Jean Chin Yu ^a   Gerona, Roy R ^b  

^a LOMA LINDA UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Intracranial hemorrhage; Rivaroxaban

Indexed keywords

BLOOD CLOTTING FACTOR 8; FRESH FROZEN PLASMA; LABETALOL; PROTHROMBIN COMPLEX; RIVAROXABAN; WARFARIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; MORPHOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

ADULT; ARTICLE; BLOOD PRESSURE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY FUNCTION; MALE; RECOMMENDED DRUG DOSE; ATRIAL FIBRILLATION; CHEMICALLY INDUCED; COMPLICATION; FATALITY; STROKE; VERY ELDERLY;

AGED, 80 AND OVER; ATRIAL FIBRILLATION; FACTOR XA INHIBITORS; FATAL OUTCOME; HUMANS; INTRACRANIAL HEMORRHAGES; MALE; MORPHOLINES; STROKE; THIOPHENES;

EID: 84903821965     PISSN: 1936900X     EISSN: 19369018     Source Type: Journal    
DOI: 10.5811/westjem.2014.2.19440     Document Type: Article

References (18)

1. Kubitza D, Becka M, Voith B, et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther. 2005;78: 412-421 (Pubitemid 41393676)
2. Perzborn E, Roehrig S, Straub A, et al. Rivaroxaban: A New Oral Factor Xa Inhibitor. Arterioscler Thromb Vasc Bio. 2010;30: 376-381
3. Winstanley L, Chen R. New thrombin and factor Xa inhibitors for primary and secondary prevention of ischaemic stroke. CNS Neurol Disord Drug Targets. 2013;12: 242-251
4. Kakar P, Watson T, Lip GY. Rivaroxaban. Drugs Today (Barc). 2007;43: 129-136 (Pubitemid 46658568)
5. Turpie AG. New oral anticoagulants in atrial fibrillation. Eur Heart J. 2008;29: 155-165
6. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365: 883-891
7. EINSTEIN Investigators, Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363: 2499-2510
8. Prandoni P. Anticoagulant treatment of pulmonary embolism: impact and implications of the EINSTEIN PE study. Eur J Haematol. 2012;89: 281-287
9. Brem E, Koyfman A, Foran M. Review of recently approved alternatives to anticoagulation with warfarin for emergency clinicians. J Emerg Med. 2013;45: 143-149
10. Körber MK, Langer E, Ziemer S, et al. Measurement and Reversal of Prophylactic and Therapeutic Peak Levels of Rivaroxaban: An In Vitro Study. Clin Appl Thromb Hemost. 2013 Jul 5. [Epub ahead of print]
11. Mueck W, Becka M, Kubitza D, et al. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct factor Xa inhibitor - in healthy subjects. Int J Clin Pharmacol Ther. 2007;45: 335-344 (Pubitemid 46895052)
12. Helin TA, Pakkanen A, Lassila R, et al. Laboratory Assessment of Novel Oral Anticoagulants: Method Suitability and Variability Between Coagulation Laboratories. Clin Chem. 2013;59: 807-814
13. van Veen J, Smith J, Kitchen S, et al. Normal prothrombin time in the presence of therapeutic levels of rivaroxaban. Br J Haematol. 2013;160:859-861
14. Kubitza D, Becka M, Mueck W, et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol. 2010;70: 703-712
15. Hori M, Matsumoto M, Tanahashi N, et al. Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation-subanalysis of J-ROCKET AF for patients with moderate renal impairment. Circ J. 2013;77: 632-638
16. Samama MM. Use of low-molecular-weight heparins and new anticoagulants in elderly patients with renal impairment. Drugs Aging. 2011;28: 177-193
17. Graff J, Harder S. Anticoagulant Therapy with the Oral Direct Factor Xa Inhibitors Rivaroxaban, Apixaban and Edoxaban and the Thrombin Inhibitor Dabigatran Etexilate in Patients with Hepatic Impairment. Clin Pharmacokinet. 2013;52: 243-254
18. Alberts MJ, Eikelboom JW, Hankey GJ. Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation. Lancet Neurol. 2012;11: 1066-1081